Press Releases Innate Pharma

Equities

IPH

FR0010331421

Market Closed - Euronext Paris Other stock markets 11:35:28 2024-04-26 am EDT			5-day change	1st Jan Change
2.245 ^EUR	+2.98%		+6.40%	-14.31%

Apr. 15	Sanofi: progress in hematology trial	CF
Apr. 15	Innate Pharma: progress in hematology trial	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innate Pharma : Brochure AG	Apr. 22	PU
Innate Pharma : Report of the Executive Board at the Annual Shareholder's Meeting of May 2024	Apr. 22	PU
Innate Pharma : Table of Financial Resolutions 2024	Apr. 22	PU
Innate Pharma : Extraordinary and Ordinary General Meeting	Apr. 16	PU
INNATE PHARMA ANNOUNCES ADVANCEMENT OF SANOFI-DEVELOPED NK CELL ENGAGER SAR443579/IPH6101 PROGRESSING TO PHASE 2 FOR BLOOD CANCER PATIENTS	Apr. 16	AQ
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients	Apr. 15	BU
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024	Apr. 15	BU
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate	Apr. 10	BU
Innate Pharma Announces Its Participation in Upcoming Investor Conference	Apr. 09	BU
INNATE PHARMA FILES ITS 2023 UNIVERSAL REGISTRATION DOCUMENT AND 2023 ANNUAL REPORT ON FORM 20-F	Apr. 08	AQ
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F	Apr. 05	BU
Innate Pharma Reports Full Year 2023 Financial Results and Business Update	Mar. 21	BU
Innate Pharma Announces Its Participation to Upcoming Investor Conference	Mar. 19	BU
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results	Mar. 14	BU
INNATE PHARMA SA - FIRST PATIENT DOSED IN PHASE 1/2 STUDY OF IPH6501 IN RELAPSED, REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA	Mar. 07	AQ
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma	Mar. 06	BU
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024	Mar. 06	BU
INNATE PHARMA ANNOUNCES ITS PARTICIPATION TO UPCOMING INVESTOR CONFERENCE	Feb. 22	AQ
INNATE PHARMA ANNOUNCES U.S. FDA LIFTS PARTIAL CLINICAL HOLD ON LACUTAMAB CLINICAL PROGRAM	Jan. 05	AQ
INNATE PHARMA STRENGTHENS LEADERSHIP AND APPOINTS TWO NEW MEMBERS TO ITS EXECUTIVE BOARD	Jan. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Innate Pharma

Equities

IPH

FR0010331421

Press Releases

Filters